Shares of Nuvectra Corp (NASDAQ:NVTR) have been given an average rating of “Buy” by the six analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $23.67.
Several equities analysts have recently commented on the stock. BidaskClub downgraded shares of Nuvectra from a “buy” rating to a “hold” rating in a report on Saturday. Zacks Investment Research downgraded shares of Nuvectra from a “hold” rating to a “sell” rating in a report on Thursday. JMP Securities boosted their target price on shares of Nuvectra from $18.00 to $23.00 and gave the stock a “market outperform” rating in a report on Wednesday, August 8th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $21.00 target price on shares of Nuvectra in a report on Wednesday, August 8th.
In related news, President Joseph Paul Hanchin sold 1,250 shares of the company’s stock in a transaction on Monday, August 20th. The shares were sold at an average price of $20.43, for a total transaction of $25,537.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 4.60% of the stock is currently owned by insiders.
NASDAQ:NVTR traded down $0.76 during trading hours on Monday, hitting $18.38. 133,023 shares of the stock traded hands, compared to its average volume of 200,260. The company has a debt-to-equity ratio of 0.42, a current ratio of 7.63 and a quick ratio of 7.35. Nuvectra has a 1 year low of $7.60 and a 1 year high of $25.17. The company has a market capitalization of $336.33 million, a P/E ratio of -4.36 and a beta of -0.34.
Nuvectra (NASDAQ:NVTR) last issued its quarterly earnings results on Monday, October 29th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.01). Nuvectra had a negative net margin of 87.94% and a negative return on equity of 65.86%. The firm had revenue of $14.22 million for the quarter, compared to analysts’ expectations of $12.38 million. On average, sell-side analysts anticipate that Nuvectra will post -3.44 earnings per share for the current fiscal year.
Nuvectra Corporation, a neuromodulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. It operates through two segments, Nuvectra and NeuroNexus. The company offers Algovita spinal cord stimulation system that is used for the treatment of chronic pain of the trunk and limbs.
Recommended Story: Day Trading
Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.